AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival in ATTR-CM patients, in all mutant and wild-type subjects.
SAN FRANCISCO , March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the 31 st Annual ROTH Conference on Monday, March 18 th at 8:30 a.m. PDT in Orange County, CA.
ATTRibute-CM study design, which incorporates feedback from the FDA , has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed by a 30-month endpoint of mortality and cardiovascular-related hospitalizations Trial sites
SAN FRANCISCO , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it will host an investor webcast
SAN FRANCISCO , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at two upcoming investor conferences. SVB Leerink Global Healthcare Conference The company will present on Thursday, February 28 , 2019 at 11:00 a.m. ET.
SAN FRANCISCO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th at 4:30 p.m. PST in San Francisco, CA.
